Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication February 1, 2007
- Accepted for publication July 30, 2007
- Published online October 1, 2007.
Article Versions
- previous version (September 14, 2007 - 11:28).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2007 by Society of Nuclear Medicine
Author Information
- Konstantin P. Zhernosekov 1 ,
- Dimitry V. Filosofov 2 ,
- Richard P. Baum 3 ,
- Peter Aschoff 4 ,
- Heiner Bihl 4 ,
- Anatoli A. Razbash 5 ,
- Markus Jahn 1 ,
- Mark Jennewein 1 and
- Frank Rösch 1
- 1Institute of Nuclear Chemistry, Johannes Gutenberg-Universität Mainz, Mainz, Germany; 2Joint Institute of Nuclear Research, LNP, Dubna, Russian Federation; 3Department of Nuclear Medicine/Center for PET-CT, Zentralklinik Bad Berka, Bad Berka, Germany; 4Klinik für Nuklearmedizin und PET-Center, Klinikum Stuttgart−Katharinenhospital, Stuttgart, Germany; and 5Cyclotron Co. Ltd., Obninsk, Russian Federation
- For correspondence or reprints contact: Frank Rösch, PhD, Institute of Nuclear Chemistry, Fritz-Strassmann-Weg 2, Johannes Gutenberg-Universität Mainz, D-55128 Mainz, Germany. E-mail: frank.roesch{at}uni-mainz.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors
- A First-in-Human Study of 68Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways
- Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor
- Upregulation of Key Molecules for Targeted Imaging and Therapy
- Novel PET Imaging of Atherosclerosis with 68Ga-Labeled NOTA-Neomannosylated Human Serum Albumin
- Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas
- 68Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification: Comparison to Conventional 51Cr-EDTA
- Development and Pre-clinical Evaluation of New 68Ga-NOTA-folate Conjugates for PET Imaging of Folate Receptor-positive Tumors
- Ethanol-Based Post-processing of Generator-Derived 68Ga Toward Kit-Type Preparation of 68Ga-Radiopharmaceuticals
- Free Somatostatin Receptor Fraction Predicts the Antiproliferative Effect of Octreotide in a Neuroendocrine Tumor Model: Implications for Dose Optimization
- 68Ga-DOTANOC PET/CT for Baseline Evaluation of Patients with Head and Neck Paraganglioma
- Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
- Nanoparticles Modified by Encapsulation of Ligands with a Long Alkyl Chain to Affect Multispecific and Multimodal Imaging
- Imaging carotid body chemodectomas with 68Ga-DOTA-NOC PET-CT
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
- 68Ga PET/CT Ventilation-Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT
- 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol
- 68Ga-DOTANOC PET/CT Allows Somatostatin Receptor Imaging in Idiopathic Pulmonary Fibrosis: Preliminary Results
- Radiolabeled Bicyclic Somatostatin-Based Analogs: A Novel Class of Potential Radiotracers for SPECT/PET of Neuroendocrine Tumors
- Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
- Impurity in 68Ga-Peptide Preparation Using Processed Generator Eluate
- Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors
- Reply: Impurity in 68Ga-Peptide Preparation Using Processed Generator Eluate
- A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression
- Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
- Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice